Inactive Instrument
Checkmate Pharmaceuticals, Inc. Stock
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 2018-12-11 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 2022-05-30 |
James Wooldridge
CTO | Chief Tech/Sci/R&D Officer | 60 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 2022-05-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 5/31/22 | Issuer sale | Director | 36,778 | 0.1700% | ||
| 5/31/22 | Issuer sale | Chief Financial Officer | 278,480 | 1.2874% | ||
| 5/31/22 | Issuer sale | Chief Executive Officer | 279,437 | 1.2919% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +0.38% | - | - | 231M | |
| +2.07% | +13.76% | +65.44% | +106.53% | 71.56B | |
| -3.50% | -4.77% | +30.58% | +59.00% | 54.43B | |
| -1.23% | -5.81% | -3.34% | +453.72% | 27.59B | |
| -1.27% | -1.57% | +46.46% | +6.09% | 23.91B | |
| -1.07% | -2.99% | -19.37% | -15.42% | 23.14B | |
| -0.64% | +0.65% | +37.95% | -20.63% | 18.65B | |
| +0.35% | +12.02% | +257.19% | +466.50% | 18.64B | |
| -0.95% | -3.52% | +20.04% | +613.01% | 16.01B | |
| -0.16% | -6.94% | +30.79% | +133.91% | 12.54B | |
| Average | -0.69% | +4.06% | +51.75% | +200.30% | 29.61B | |
| Weighted average by Cap. | -0.64% | +3.63% | +49.26% | +161.16% |
Employees
31
